Biocon Biologics Strengthens UK Presence with Approval for Two Denosumab Biosimilars

Biologics has received marketing approval from the UK’s MHRA for its Denosumab biosimilars that is Vevzuo and Evfraxy, marking a significant step in its global expansion strategy. Vevzuo is approved for treating bone complications in adults with advanced cancer, while Evfraxy will address osteoporosis and bone loss in men and women at risk of fractures. Both biosimilars have been proven clinically equivalent in safety and efficacy to the reference product. With this approval, following a prior European Commission nod, Biocon is set to unlock new market opportunities in Europe’s biosimilar space, enhancing access and affordability in critical therapies. This is a strong strategic move in Biocon’s push to scale its presence in regulated markets. Follow me for more such updates, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.